ABTL-0812

Catalog No.S9611 Synonyms: α-Hydroxylinoleic acid

For research use only.

ABTL0812 (α-Hydroxylinoleic acid, LP-10218, SCLN-0812) inhibits Akt/mTOR axis by inducing the overexpression of TRIB3 and activating autophagy in lung squamous carcinoma cell lines. ABTL0812 also induces AMPK activation and ROS accumulation.

ABTL-0812 Chemical Structure

CAS No. 57818-44-7

Purity & Quality Control

Choose Selective Akt Inhibitors

Other Akt Products

Biological Activity

Description ABTL0812 (α-Hydroxylinoleic acid, LP-10218, SCLN-0812) inhibits Akt/mTOR axis by inducing the overexpression of TRIB3 and activating autophagy in lung squamous carcinoma cell lines. ABTL0812 also induces AMPK activation and ROS accumulation.
Targets
Akt [1] mTOR [1]
In vitro

ABTL0812 inhibits Akt/mTOR axis by inducing the overexpression of TRIB3 and activating autophagy in lung squamous carcinoma cell lines. Furthermore, treatment with ABTL0812 also induces AMPK activation and ROS accumulation. Moreover, combination of ABTL0812 with chemotherapy markedly increases the therapeutic effect of chemotherapy without increasing toxicity. Combination of ABTL0812 and chemotherapy induces nonapoptotic cell death mediated by TRIB3 activation and autophagy induction.[1]

In vivo

ABTL0812 enhances carboplatin and paclitaxel antitumor activity both in adenocarcinomas and squamous lung xenografts.[1]

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: Human adenocarcinoma cell lines (A549, NCI-H1975), squamous-cell carcinoma (NCI-H520, NCI-H157)
  • Concentrations: 0–200 μM
  • Incubation Time: 72 h
  • Method:

    Briefly, for docetaxel studies, subconfluent cultures of adenocarcinoma lung cancer cells are incubated for 72 hr in the presence of an increasing concentration of ABTL0812 (0–200 μM), docetaxel (0–100 μM) or the combination of increasing doses of docetaxel with ABTL0812 20 μM. For paclitaxel studies, subconfluent cultures of adenocarcinoma and squamous lung cancer cell lines are incubated for 48 hr in the presence of an increasing concentration of paclitaxel (0–1 μM) or the combination of increasing doses of paclitaxel with sub-IC50 concentrations of ABTL0812 (5–30 μM).

Animal Research:

[1]

  • Animal Models: 5-week-old female athymic nude Foxn 1nu nu/nu mice
  • Dosages: 30 mg/kg, 120 mg/kg
  • Administration: Oral gavage

Chemical Information

Molecular Weight 296.44
Formula

C18H32O3

Density 1.0 g/mL
CAS No. 57818-44-7
Storage 2 years -20°C liquid
Smiles CCCCCC=CCC=CCCCCCCC(C(=O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02201823 Completed Drug: ABTL0812 Cancer Ability Pharmaceuticals SL|Hospital Clinic of Barcelona|Institut Català d''Oncologia February 2014 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy ABTL-0812 | ABTL-0812 supplier | purchase ABTL-0812 | ABTL-0812 cost | ABTL-0812 manufacturer | order ABTL-0812 | ABTL-0812 distributor